commercial discussions , page-21

Below are some notes -

Reposted without links to infringe copyright

* Over 80 Companies testing Mixngo

* Strong Balance sheet - sufficiently funded to end Q1 2014 at current burn ($2.5-$3m pa)

* "And we are at the moment entering into A NUMBER OF CONTRACTS"

* "We would expect to be CASHFLOW POSITIVE through the course of 2013 is a reality" :)

* Up to 90% saving in key component of the tests "Antibody"

* "Our reactions take place in minutes rather than overnight"

* When talking about IVD Companies -

"Our focus is really further up the value chain to the manufacturers of the tests - The likes of Beckman - Roche - Abbott - Diasorin and in some cases we are well advanced in our dealings with these people - They are ALL using our process in house to determine the merits in their manufacturing environment"

* "Point of Care is a burgeoning area in the healthcare environment and were VERY MUCH involved with that and I suspect that there will be NEWS in that area in the not too distant future"

My thoughts are and backed up by info presented in all ADO announcements is that we have deals coming - Note I said deals - Yes there was a long time between drinks between the Merck signing and the Ebioscience signing but it is quite obvious the snowball is gaining momentum.

If I am correct and we see a signing with Philips in the Point of Care market this will see a strong rating of the shareprice to much higher levels - These companies dont adopt new technology easily and when they do you have royalties coming for years and years to come.

If we are indeed involved with Philips Magnotech device as has been talked about previously on these threads then we could see large upfront payments and royalties although percentage wise royalties would not be as large my guess would be for global sales annually in the hundreds of millions of dollars.